Get the Daily Brief
Latest Biotech News
GSK expands oligonucleotide and PAH bets: two deals push immunology and pulmonary pipeline
GSK closed a deal to license two Frontier Biotechnologies siRNA assets and separately bought 35Pharma to add a pulmonary hypertension candidate, executing a two‑pronged growth push into...
FDA tightens bar on gene therapies — Regenxbio, UniQure face fresh regulatory hurdles
The FDA pushed back on pivotal gene therapy submissions, citing trial design, control group and endpoint issues in public rejection letters and company disclosures. REGENXBIO received an FDA...
FDA clears Ascendis’ once‑weekly dwarfism shot: accelerated approval granted
The FDA granted accelerated approval to Ascendis Pharma’s once‑weekly TransCon CNP (Yuviwel) for children with achondroplasia, breaking BioMarin’s prior monopoly in the indication. The approval...
Blackstone backs Teva with $400M — funds Sanofi‑partnered anti‑TL1A development
Private equity firm Blackstone Life Sciences agreed to provide up to $400 million to support Teva’s development of duvakitug, an anti‑TL1A antibody partnered with Sanofi for inflammatory bowel...
Candid to go public via RallyBio reverse merger — $505M in new funding
Candid Therapeutics will go public through a reverse merger with RallyBio and simultaneously raised $505 million in a private placement to advance its T‑cell engager pipeline targeting autoimmune...
Sequencing arms race... Big vendors roll new high‑throughput options, price pressure hits Illumina
Industry announcements at AGBT and related venues signaled a sharpening competition for ultra‑high throughput sequencing: Element Biosciences, Ultima Genomics, Roche and Complete Genomics revealed...
Biotech funding roundup: $150M mental‑health play and top February rounds
Investors continued to fund health‑focused companies: Grow Therapy closed a $150 million Series D to expand employer and health‑system partnerships, while sector trackers flagged the largest...
Moderna settles long-running mRNA patent fight: $950M now, up to $2.25B possible
Moderna agreed to a major settlement with Arbutus Biopharma and Roivant’s Genevant, paying $950 million upfront to resolve patent claims tied to its Covid-19 vaccine, with contingent payments that...
Theravance collapses R&D after pivotal failure — workforce halved
Theravance Biopharma announced a sweeping retrenchment after its Phase 3 trial of ampreloxetine missed the primary endpoint, prompting the company to cease all R&D activity and cut about half its...
FDA tightens rare‑disease bar: Regenxbio, UniQure meet resubmission demands
Two high-profile gene therapy programs ran into fresh regulatory headwinds as the FDA pushed for more rigorous evidence. In a public complete response letter, the agency told Regenxbio that its...
Private capital backs Teva’s IBD push: Blackstone to fund anti‑TL1A program
Blackstone Life Sciences agreed to provide up to $400 million to Teva to accelerate development of duvakitug, an anti‑TL1A antibody partnered with Sanofi that is in Phase 3 for ulcerative colitis...
GSK bulks up oligonucleotide and PAH pipelines with two big buys
GlaxoSmithKline struck two strategic deals this week: a licensing pact with China’s Frontier Biotechnologies for two siRNA immunology candidates and an outright $950 million cash acquisition of...
Ascendis wins FDA nod for once‑weekly dwarfism shot — market shifts
The FDA granted accelerated approval to Ascendis Pharma’s TransCon CNP (now Yuviwel), a once‑weekly injection for children with achondroplasia two years and older, ending BioMarin’s de facto...
AGBT sparks high‑throughput sequencing war — Illumina faces new challengers
Announcements at the Advances in Genome Biology and Technology meeting painted a picture of intensifying competition in high‑throughput sequencing. Multiple vendors unveiled or detailed...
Earendil and WuXi XDC ink up to $885M ADC partnership
Earendil Labs entered a strategic collaboration with WuXi XDC to license payload‑linker and manufacturing technologies for antibody‑drug conjugates, a deal valued up to approximately $885 million...
Asahi Kasei buys Aicuris for €780M — antiviral portfolio expands
Asahi Kasei agreed to acquire Aicuris Anti‑infective Cures AG in an all‑cash transaction valued at €780 million (about $920 million), adding marketed cytomegalovirus products and a herpes therapy...
Candid goes public: reverse merger with Rallybio and $505M raise
Candid Therapeutics will go public via a reverse merger with Rallybio, taking the combined company forward under Candid’s name and ticker CDRX. The transaction accompanies a $505 million private...
FDA presses for sham‑controlled trial — uniQure’s Huntington bid stalls
The FDA has told uniQure that its existing evidence for the AMT‑130 Huntington’s gene therapy is insufficient and has recommended a randomized, sham surgery–controlled study before considering...
Theravance winds down R&D — halves workforce after Phase 3 loss
Theravance Biopharma announced an end to its R&D organization and plans to cut roughly 50% of its workforce after ampreloxetine failed a pivotal Phase 3 trial in multiple system atrophy. The...
Blackstone backs Teva: $400M to accelerate Sanofi‑partnered IBD drug
Private equity arm Blackstone Life Sciences agreed to provide Teva Pharmaceutical with up to $400 million over four years to support development of duvakitug, an anti‑TL1A antibody co‑developed...